Don't Ignore This Chart!

BioMarin Next In Line For Breakout Among Biotechs?


BioMarin Pharmaceutical (BMRN), like the overall biotech industry ($DJUSBT), has struggled for the past 18 months to clear overhead price resistance.  But over the past couple trading sessions, we have seen one biotech company after another clear resistance on strong volume and accelerate.  It appears that BMRN is awaiting its turn.  While its gains this week have been strong, the best may await on a breakout.   Here's the longer-term weekly chart:

You can see that interest is picking up in BMRN as weekly volume is its highest in eight weeks to accompany a 9.7% move higher.  But a major breakout at 100 remains.  Money is definitely rotating towards biotech stocks and healthcare (XLV) as you can see that relative downtrend line (biotechs vs. S&P 500) has broken.  The XLV now has a SCTR reading of 95.6, the highest of any sector, and biotechs are the primary reason why as they've gained 7.66% as a group in the past week alone .  Given the weekly RSI and stochastic at 60 and 43, respectively, it would seem as if the BMRN party may just be getting started.  We do need that breakout on increasing volume to confirm, however.

Happy trading!



Announcement from the Author

{{ announcement.content }}

Tom Bowley
About the author: co-founded Invested Central in 2004 and served as the site's Chief Market Strategist for more than 10 years. Invested Central provides stock market education and guidance for those interested in making their own financial decisions. During his tenure at Invested Central, Tom co-hosted Market Open LIVE, a national radio broadcast that covered many of the largest markets across the U.S. In addition, he has spoken at various conferences throughout the United States and Canada and has taught thousands of traders across the globe how to trade equities more wisely with an emphasis on managing risk and intermarket relationships. Learn More
Subscribe to Don't Ignore This Chart! to be notified whenever a new post is added to this blog!
comments powered by Disqus